Strikingly, anti-IL-1β treatment counteracted PMN-MDSC-mediated immunosuppression and potently prolonged the survival of female mice, further providing the rationale for clinical testing of IL-1β inhibitors in cancer patients [31]. This evidence concerns the gene IL1B and cancer.